文献速递妇科

地诺孕素治疗子宫腺肌病患者疼痛症状的有效性和安全性评估:一项随机、双盲、多中心、安慰剂对照研究

Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
PubMed 文献 · Fertil Steril · 2017-09-11

本项在日本开展的III期随机双盲多中心安慰剂对照研究纳入67例子宫腺肌病患者,比较地诺孕素2 mg/d口服与安慰剂治疗16周的效果。结果显示地诺孕素组疼痛评分和视觉模拟量表较基线的下降显著大于安慰剂组(P<.001),治疗期间几乎所有地诺孕素组患者出现不规则子宫出血,1例出现轻度贫血,未见重度贫血病例。作者认为地诺孕素对不伴严重子宫增大或严重贫血的子宫腺肌病相关疼痛症状有效且耐受性良好。

要点

  • 地诺孕素2 mg/d口服治疗16周,疼痛评分和视觉模拟量表较基线下降显著大于安慰剂组(P<.001)。
  • 治疗期间几乎所有地诺孕素组患者出现不规则子宫出血,1例出现轻度贫血,未见重度贫血。
  • 作者认为地诺孕素对不伴严重子宫增大或严重贫血的子宫腺肌病相关疼痛有效且耐受性良好。

核心结论

  • 作者认为地诺孕素对不伴严重子宫增大或严重贫血的子宫腺肌病相关疼痛症状有效且耐受性良好。

研究设计与样本

  • III期、随机、双盲、多中心、安慰剂对照研究,在日本临床研究站点开展,纳入67例子宫腺肌病患者。
  • 患者随机接受地诺孕素2 mg/d口服或安慰剂治疗16周;合并贫血者在随机化前先治疗贫血。
  • 主要终点为基线至治疗后疼痛评分的变化,采用0至3分口头评定量表,按工作能力受限程度和镇痛药需求定义疼痛严重程度;视觉模拟量表作为另一疼痛参数。

主要发现

  • 治疗结束时,地诺孕素组疼痛评分和视觉模拟量表较基线的下降显著大于安慰剂组(P<.001)。
  • 治疗期间,几乎所有接受地诺孕素治疗的患者出现不规则子宫出血,1例出现轻度贫血,未见重度贫血病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with symptomatic adenomyosis. DESIGN: Phase III, randomized, double-blind, multicenter, placebo-controlled study. SETTING: Clinical study sites in Japan. PATIENT(S): Sixty-seven patients with adenomyosis. INTERVENTION(S): Patients were randomly assigned to receive DNG (2 mg/d, orally) or placebo for 16 weeks. In cases of complicated anemia, patients were treated for anemia before randomization. MAIN OUTCOME MEASURE(S): The primary end point was the change from baseline to after treatment pain score, using zero- to three-point verbal rating scales that defined pain severity according to limited ability to work and need for analgesics. The visual analogue scale was used as another pain parameter. RESULT(S): Decreases from baseline in the pain score and the visual analogue scale at the end of treatment were significantly more in the DNG group than in the placebo group (P<.001). During the treatment period, almost all of the patients treated with DNG experienced irregular uterine bleeding and one patient had mild anemia. No severe cases of anemia were observed. CONCLUSION(S): These results suggest that DNG is effective and well tolerated in the treatment for painful symptoms associated with adenomyosis not complicated by severe uterine enlargement or severe anemia. CLINICAL TRIAL REGISTRATION NUMBER: JapicCTI-142642(en).

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Osuga Y, Fujimoto-Okabe H, Hagino A, et al. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril. 2017. PMID: 28911934. doi:10.1016/j.fertnstert.2017.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。